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decreased while PGA increased. A 1998–2003 linear extrapo-
lated market share would have predicted a crossing of the two
curves around 2005, reinforced by the new 1st line indication of
PGA authorized by the EMEA in 2002. This did not occur which
might be explained by the non-reimbursement of PGA for ﬁrst
line therapy in Italy. Accordingly, yearly Padova area drug spend-
ing was €150,000 less than predicted, on a €600,000 yearly
budget. The comparison of IMS data shows two countries where
the BB are still prescribed more than PGA, Italy and Germany.
The latter is a country where physicians’ fees are reduced if their
glaucoma prescription costs exceed their government set budget.
PGA monotherapy treatment persistence was longer than with
BB, according to Padova and UK GPRD data, in PGA-naive
patients. This holds true for ﬁrst line and second line treatment
(UK GPRD); the persistency of a second line PGA equaled ﬁrst
line BB treatment. A short treatment persistency is known to be
associated with high cost and disease progression. CONCLU-
SIONS: Health care regulation impacted glaucoma prescribing
and might be one of the reasons for differences observed between
the ﬁve European countries. Evaluations of both the cost conse-
quences beyond the drug budget and the public health impact
should always accompany the establishment of health care
regulations.
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OBJECTIVES: This analysis evaluated whether the Dermatology
Life Quality Index (DLQI) and the Psoriasis Area and Severity
Index (PASI) have different responsiveness to measure change
of treatment effect in moderate to severe psoriasis patients.
METHODS: In PHOENIX I, 766 patients were randomized to
ustekinumab 45 mg or 90 mg at weeks 0 and 4 and then q12
weeks thereafter, or placebo at weeks 0 and 4 with crossover
to ustekinumab at week 12. Ustekinumab-randomized patients
achieving PASI75 response at weeks 28 and 40 were re-
randomized at week 40 to continue maintenance ustekinumab or
be withdrawn from treatment until loss of response. DLQI and
PASI were assessed at weeks 0, 2, 12, 28, 40 and 52. Multiple
regression models were used to assess treatment effect on DLQI
by adjusting for PASI improvement. RESULTS: Signiﬁcantly
greater proportions of patients receiving ustekinumab achieved
PASI75 response (66.7%) and clinically meaningful improve-
ment (5 points) in DLQI (67.8%) compared with placebo
(3.1% and 6.0%, each p < 0.001) at week 12. There was a
signiﬁcant correlation between the change in DLQI and change
in PASI (r = 0.65, p < 0.001). After adjustment for baseline
DLQI, baseline PASI, and change in PASI, ustekinumab was still
associated with signiﬁcant improvement in DLQI (p < 0.001).
For patients originally randomized to ustekinumab, the median
% improvement from baseline was higher in DLQI (37.5%) than
in PASI (21.4%) at week 2, with 11.4% of patients achieving a
DLQI score of 1, but only 1% achieving a PASI75 response. At
week 28 and 40, the DLQI and PASI achieved and maintained
similar improvements of 90% from baseline. For those who
achieved and maintained a PASI75 response from week 12
through week 40, but lost response at week 52, the median
improvement in DLQI decreased more signiﬁcantly (100% at
week 40 to 46% at week 52, a 54% reduction) than PASI that
decreased from 88.9% at week 40 to 57.6% at week 52 (35.0%
reduction). CONCLUSIONS: The DLQI may be more respon-
sive to change of disease status due to treatment intervention
than PASI.
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OBJECTIVES: The primary treatment for minor to moderate
bleeding disorders in haemophilia patients with inhibitors is
either rFVIIa or aPCC. The efﬁcacy of both products has been
evaluated in individual studies; however there has not been an
overall review and attempt to establish a valid estimate of the
effectiveness of rFVIIa and aPCC. We undertook a systematic
review of the literature in an attempt to establish robust estimates
of the efﬁcacy, speed of bleed resolution, and adverse event
proﬁle of both rFVIIa and aPCC. METHODS: We identiﬁed 11
open-label cohort studies, six randomized clinical trials, includ-
ing two head-to-head clinical trials and a meta-analysis. The
deﬁnition of efﬁcacy varies between these studies, but is usually a
composite measure of deﬁnite relief of pain, reduction in the size
of the haemorrhage, and cessation of bleeding. The individual
making the interpretation of efﬁcacy (i.e., the clinician, the
patient/caregiver, or a combination of both) and the time from
treatment initiation to the recording of the efﬁcacy endpoint also
varies across the studies. RESULTS: Overall, estimates of efﬁcacy
based on randomized clinical trials using dosing regimens in line
with guidelines are higher for rFVIIa (81%–91%) than for aPCC
(64–80%). Conclusions from a meta-analysis suggest that treat-
ment with rFVIIa may be associated with a faster time to joint
bleed resolution than aPCC due to higher efﬁcacy levels at 12, 24
and 36 hour time points. The results from a comparative trial
support the improved efﬁcacy rates associated with rFVIIa com-
pared to aPCC. CONCLUSIONS: In general, the studies do
report higher efﬁcacy and bleed cessation rates for rFVIIa than
for aPCC; however, the measurement of effectiveness of the
agents is open to interpretation due to variety of methods being
used to evaluate effectiveness. Further head-to-head trials should
incorporate a standardized measurement for deﬁning efﬁcacy.
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OBJECTIVES: To review how the Fabry Outcome Survey (FOS),
a physician-driven multinational database supported by Shire
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HGT, has contributed to advancing the understanding and man-
agement of Fabry disease—a rare lysosomal storage disorder
caused by deﬁciency of the enzyme a-galactosidase A.
METHODS: FOS—a prospective database that collects informa-
tion on demographics, signs and symptoms, investigations and
patient-reported outcomes for patients with a conﬁrmed diagno-
sis of Fabry disease—was established in 2001. Working groups
were appointed to analyse, interpret and publish data to further
the understanding of the natural history of the disease and the
response to enzyme replacement therapy with agalsidase alfa.
RESULTS: As of May 2008, 19 countries have enrolled 1528
patients (799 females, 729 males). Of these, 138 are girls and 123
boys less than 18 years of age. Signiﬁcant peer-reviewed pub-
lished ﬁndings include evidence of the range and progression of
signs and symptoms in males and females (Mehta et al., 2004;
Deegan et al., 2006), which have shown that affected women are
not simply ‘carriers’ of the disease, but may experience a wide
range of symptoms. FOS has also demonstrated that boys and
girls may experience symptoms from an early age (Ramaswami
et al., 2006). Evidence on the effectiveness of agalsidase alfa (2
years of treatment) on various signs and symptoms such as renal
function (Schwarting et al., 2006), pain (Hoffmann et al., 2007a)
and gastrointestinal symptoms (Hoffmann et al., 2007b) has also
been reported. CONCLUSIONS: FOS has provided an impor-
tant evidence base that has helped to advance the management of
Fabry disease in males and females across all ages. Evidence on
the onset and progression of the disease in females and children
has been especially important to help achieve an early diagnosis,
support clinical decision making and guide management to help
optimize patient care.
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OBJECTIVES: The study was performed to estimate the preva-
lence of obesity and associated risk factors such as type 2 dia-
betes or dyslipidaemia in the Korean adult population.
METHODS: The third Korean National Health and Nutrition
Examination Survey in 2005 (KNHANES III) data was used. For
the estimation of prevalence of overall obesity (deﬁned by body
mass index, BMI) in this report, subjects were selected as adults
over 18 years old and completed health examinations. Each
sampling weights was used for the analysis. Weights were given
as an inverse of the probability of selection, and a non-response
adjustment weight. Prevalence of obesity was calculated as the
weighted number of obese people divided by the weighted
number of all eligible people. Numbers of people with obesity
and related metabolic abnormalities were estimated with multi-
plying the calculated prevalence by the total Korean population.
RESULTS: Among the Korean adult population (age 18 years
or more), proportions of people with BMI  25.0 kg/m2,
27.0 kg/m2 and 30.0 kg/m2 were estimated to 28.1%, 13.2%
and 3.2%, respectively. Within the group BMI  27.0 kg/m2,
9.1% had type 2 diabetes. Among them, 64.6% were diagnosed
for T2DM and 21.5% of the diagnosed were untreated. In the
same group, the people who had any HDL/TG abnormality
without T2DM were 49.4% and only 8.2% of them were pre-
viously diagnosed by physician. Overall 70% of the people with
BMI 27.0 kg/m2 or higher had at least one metabolic abnorma-
lity like T2DM, HDL/TG abnormality, pre-diabetes or high
serum LDL-C. CONCLUSIONS: This study showed the current
situation of obesity and related metabolic abnormalities among
Korean population based on KNHANES III data. It will be a
good reference for the development of national strategy to
improve the management or treatment for obese adults with
metabolic abnormalities.
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OBJECTIVES: Immune thrombocytopenic purpura (ITP) is a
rare and life-threatening autoimmune disorder characterized by
increased destruction and impaired production of blood plate-
lets by auto-antibodies. International epidemiological studies
reported yearly incidence and prevalence of respectively 2 and
10 cases/100,000 persons. No Belgian epidemiological data are
currently available. To estimate the incidence and prevalence
of adult chronic ITP in Belgium using hospital records.
METHODS: The incidence of adult chronic ITP was estimated
using the National statistics on Diagnosis Related Group for
splenectomy (DRG 650, year 2004). The prevalence was esti-
mated using the longitudinal IMS Hospital Disease Database
(year 2006), including data of 34.3% of Belgian hospitals. All
admissions to hospital with a diagnosis of Primary Thromb-
ocytopenia (ICD-9-CM 287.3) were retrieved for patients aged
>20 years. The repartition of cases by age and sex was inves-
tigated. RESULTS: A total of 229 splenectomies were per-
formed in adults in 2004. Assuming that 10–30% of
splenectomies are ITP-related and 20–40% of chronic ITP
patients are splenectomized, this results in a yearly incidence of
0.7–4.3 new ITP cases per 100,000 adults, i.e. 57–344 new
cases/year. In 2006, 657 admissions for primary thrombocy-
topenia were recorded in the Hospital Disease database, for
350 distinct adult patients. This corresponds to an estimated
prevalence of 12.6 per 100,000 adults per annum, i.e. 1020
patients. A quadratic increase of the prevalence was observed
with age: from 5.8 to 39.8 cases per 100,000 per year in the
age groups of 20–29 years to 75 years. The prevalence was
2.7 times higher in women aged 20–55 years vs. men
(p < 0.001), but similar in patients aged older. CONCLU-
SIONS: Although non-hospitalized patients were not captured
in this analysis, these Belgian incidence and prevalence data are
consistent with published international data. The prevalence of
ITP increases substantially with age. Prevalence is also higher in
women in younger age groups.
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OBJECTIVES: To determine the correlations between diseases,
patients, drugs factors and systemic lupus erythematosus (SLE)
disease activity. To establish model for predicting SLE disease
activity. METHODS: The Cross-sectional survey method was
applied, SLE patients who visit rheumatologist at Nopparat
Rajathanee hospital were interviewed during November 1, 2007
to February 29, 2008, disease duration, infection, SLE knowl-
edge, self management, stress and compliance were collected and
evaluated to ﬁnd correlation with disease activity scores (measure
by MEX-SLEDAI). Multiple Regression Analysis was applied to
identify model for predict the disease activity. RESULTS: Data
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